Identification of novel chondroprotective mediators in resolving inflammatory exudates

Journal of Immunology

Volumn 198, Issue 7, 2017, Pages 2876-2885

  Kaneva, Magdalena K ^a   Greco, Karin V ^a   Headland, Sarah E ^a   Montero Melendez, Trinidad ^a   Mori, Prashant ^b   Greenslade, Kevin ^b   Pitzalis, Costantino ^a   Moore, Adrian ^b   Perretti, Mauro ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b UCB PHARMA   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

AGGRECAN; ALPHA 1 ANTITRYPSIN; CARRAGEENAN; CELL PROTEIN; COL2A1 PROTEIN; GELSOLIN; GLYCOSAMINOGLYCAN; HEMOPEXIN; INTERLEUKIN 1BETA; MESSENGER RNA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTHRITIS; ARTICLE; CARBOHYDRATE METABOLISM; CARTILAGE; CHONDROCYTE; CHONDROPROTECTION; EXUDATE; GEL FILTRATION CHROMATOGRAPHY; GENE EXPRESSION; GLYCOSAMINOGLYCAN DEPOSITION; HISTOPATHOLOGY; IN VIVO STUDY; MALE; MEDIATOR; MOLECULAR WEIGHT; MOUSE; NONHUMAN; OSTEOARTHRITIS; PLEURISY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEOMICS; RAT; REAL TIME POLYMERASE CHAIN REACTION; SYNOVIAL FLUID; UPREGULATION; ANIMAL; C57BL MOUSE; CHEMISTRY; DISEASE MODEL; DRUG EFFECTS; EXPERIMENTAL ARTHRITIS; IMMUNOLOGY; KNEE OSTEOARTHRITIS; MASS SPECTROMETRY; PATHOLOGY; WISTAR RAT;

ANIMALS; ARTHRITIS, EXPERIMENTAL; CHONDROCYTES; DISEASE MODELS, ANIMAL; EXUDATES AND TRANSUDATES; MALE; MASS SPECTROMETRY; MICE; MICE, INBRED C57BL; OSTEOARTHRITIS, KNEE; PLEURISY; PROTEOMICS; RATS; RATS, WISTAR; REAL-TIME POLYMERASE CHAIN REACTION;

EID: 85016231850     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1601111     Document Type: Article

References (60)

1. Serhan, C. N. 2011. The resolution of inflammation: the devil in the flask and in the details. FASEB J. 25: 1441-1448.
2. Ortega-Gómez, A., M. Perretti, and O. Soehnlein. 2013. Resolution of inflammation: an integrated view. EMBO Mol. Med. 5: 661-674.
3. Medzhitov, R. 2008. Origin and physiological roles of inflammation. Nature 454: 428-435.
4. Buckley, C. D., D. W. Gilroy, and C. N. Serhan. 2014. Proresolving lipid mediators and mechanisms in the resolution of acute inflammation. Immunity 40: 315-327.
5. Szczodry, M., C. H. Coyle, S. J. Kramer, P. Smolinski, and C. R. Chu. 2009. Progressive chondrocyte death after impact injury indicates a need for chondroprotective therapy. Am. J. Sports Med. 37: 2318-2322.
6. Lohmander, L. S., P. M. Englund, L. L. Dahl, and E. M. Roos. 2007. The longterm consequence of anterior cruciate ligament and meniscus injuries: osteoarthritis. Am. J. Sports Med. 35: 1756-1769.
7. Kaneva, M. K., M. J. Kerrigan, P. Grieco, G. P. Curley, I. C. Locke, and S. J. Getting. 2014. Melanocortin peptides protect chondrocytes from mechanically induced cartilage injury. Biochem. Pharmacol. 92: 336-347.
8. Jayabalan, P., S. Hagerty, and M. H. Cortazzo. 2014. The use of platelet-rich plasma for the treatment of osteoarthritis. Phys. Sportsmed. 42: 53-62.
9. Sakata, R., S. M. McNary, K. Miyatake, C. A. Lee, J. M. Van den Bogaerde, R. A. Marder, and A. H. Reddi. 2015. Stimulation of the superficial zone protein and lubrication in the articular cartilage by human platelet-rich plasma. Am. J. Sports Med. 43: 1467-1473.
10. Sermer, C., B. Devitt, J. Chahal, R. Kandel, and J. Theodoropoulos. 2015. The addition of platelet-rich plasma to scaffolds used for cartilage repair: a review of human and animal studies. Arthroscopy 31: 1607-1625.
11. Schwab, J. M., N. Chiang, M. Arita, and C. N. Serhan. 2007. Resolvin E1 and protectin D1 activate inflammation-resolution programmes. Nature 447: 869-874.
12. Gilroy, D. W., P. R. Colville-Nash, D. Willis, J. Chivers, M. J. Paul-Clark, and D. A. Willoughby. 1999. Inducible cyclooxygenase may have anti-inflammatory properties. Nat. Med. 5: 698-701.
13. Willis, D., A. R. Moore, R. Frederick, and D. A. Willoughby. 1996. Heme oxygenase: a novel target for the modulation of the inflammatory response. Nat. Med. 2: 87-90.
14. Goldring, M. B., J. R. Birkhead, L. F. Suen, R. Yamin, S. Mizuno, J. Glowacki, J. L. Arbiser, and J. F. Apperley. 1994. Interleukin-1 beta-modulated gene expression in immortalized human chondrocytes. J. Clin. Invest. 94: 2307-2316.
15. Greco, K. V., A. J. Iqbal, L. Rattazzi, G. Nalesso, N. Moradi-Bidhendi, A. R. Moore, M. B. Goldring, F. Dell'Accio, and M. Perretti. 2011. High density micromass cultures of a human chondrocyte cell line: a reliable assay system to reveal the modulatory functions of pharmacological agents. Biochem. Pharmacol. 82: 1919-1929.
16. Grigoriadis, A. E., J. N. Heersche, and J. E. Aubin. 1996. Analysis of chondroprogenitor frequency and cartilage differentiation in a novel family of clonal chondrogenic rat cell lines. Differentiation 60: 299-307.
17. Lowe, G. N., Y. H. Fu, S. McDougall, R. Polendo, A. Williams, P. D. Benya, and T. J. Hahn. 1996. Effects of prostaglandins on deoxyribonucleic acid and aggrecan synthesis in the RCJ 3.1C5.18 chondrocyte cell line: role of second messengers. Endocrinology 137: 2208-2216.
18. McDougall, S., Y. H. Fu, G. N. Lowe, A. Williams, R. Polendo, P. D. Benya, A. Iida-Klein, M. A. Fang, and T. J. Hahn. 1996. Surface adhesion-mediated regulation of chondrocyte-specific gene expression in the nontransformed RCJ 3.1C5.18 rat chondrocyte cell line. J. Bone Miner. Res. 11: 1130-1138.
19. Dalli, J., L. V. Norling, D. Renshaw, D. Cooper, K. Y. Leung, and M. Perretti. 2008. Annexin 1 mediates the rapid anti-inflammatory effects of neutrophilderived microparticles. Blood 112: 2512-2519.
20. Livak, K. J., and T. D. Schmittgen. 2001. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 25: 402-408.
21. Kapoor, M., J. Martel-Pelletier, D. Lajeunesse, J. P. Pelletier, and H. Fahmi. 2011. Role of proinflammatory cytokines in the pathophysiology of osteoarthritis. Nat. Rev. Rheumatol. 7: 33-42.
22. Headland, S. E., H. R. Jones, L. V. Norling, A. Kim, P. R. Souza, E. Corsiero, C. D. Gil, A. Nerviani, F. Dell'Accio, C. Pitzalis, et al. 2015. Neutrophil-derived microvesicles enter cartilage and protect the joint in inflammatory arthritis. Sci. Transl. Med. 7: 315ra190.
23. Ryan, S. M., J. McMorrow, A. Umerska, H. B. Patel, K. N. Kornerup, L. Tajber, E. P. Murphy, M. Perretti, O. I. Corrigan, and D. J. Brayden. 2013. An intraarticular salmon calcitonin-based nanocomplex reduces experimental inflammatory arthritis. J. Control. Release 167: 120-129.
24. Patel, H. B., K. N. Kornerup, A. L. Sampaio, F. D'Acquisto, M. P. Seed, A. P. Girol, M. Gray, C. Pitzalis, S. M. Oliani, and M. Perretti. 2012. The impact of endogenous annexin A1 on glucocorticoid control of inflammatory arthritis. Ann. Rheum. Dis. 71: 1872-1880.
25. Norling, L. V., and M. Perretti. 2013. Control of myeloid cell trafficking in resolution. J. Innate Immun. 5: 367-376.
26. Koltsida, O., S. Karamnov, K. Pyrillou, T. Vickery, A. D. Chairakaki, C. Tamvakopoulos, P. Sideras, C. N. Serhan, and E. Andreakos. 2013. Toll-like receptor 7 stimulates production of specialized pro-resolving lipid mediators and promotes resolution of airway inflammation. EMBO Mol. Med. 5: 762-775.
27. Cash, J. L., M. D. Bass, J. Campbell, M. Barnes, P. Kubes, and P. Martin. 2014. Resolution mediator chemerin15 reprograms the wound microenvironment to promote repair and reduce scarring. [Published erratum appears in 2014 Curr. Biol. 24: 1435.] Curr. Biol. 24: 1406-1414.
28. Perez-Aso, M., L. Chiriboga, and B. N. Cronstein. 2012. Pharmacological blockade of adenosine A2A receptors diminishes scarring. FASEB J. 26: 4254-4263.
29. Dalli, J., R. A. Colas, C. Quintana, D. Barragan-Bradford, S. Hurwitz, B. D. Levy, A. M. Choi, C. N. Serhan, and R. M. Baron. 2017. Human sepsis eicosanoid and proresolving lipid mediator temporal profiles: correlations with survival and clinical outcomes. Crit. Care Med. 45: 58-68.
30. Norling, L. V., S. E. Headland, J. Dalli, H. H. Arnardottir, O. Haworth, H. R. Jones, D. Irimia, C. N. Serhan, and M. Perretti. 2016. Proresolving and cartilage-protective actions of resolvin D1 in inflammatory arthritis. JCI Insight 1: e85922.
31. Bannenberg, G. L., N. Chiang, A. Ariel, M. Arita, E. Tjonahen, K. H. Gotlinger, S. Hong, and C. N. Serhan. 2005. Molecular circuits of resolution: formation and actions of resolvins and protectins. [Published erratum appears in 2005 J. Immunol. 174: 5884.] J. Immunol. 174: 4345-4355.
32. Ruiz-Romero, C., and F. J. Blanco. 2010. Proteomics role in the search for improved diagnosis, prognosis and treatment of osteoarthritis. Osteoarthritis Cartilage 18: 500-509.
33. Biswas, S., S. Sharma, A. Saroha, D. S. Bhakuni, R. Malhotra, M. Zahur, M. Oellerich, H. R. Das, and A. R. Asif. 2013. Identification of novel autoantigen in the synovial fluid of rheumatoid arthritis patients using an immunoproteomics approach. PLoS One 8: e56246.
34. Silverman, G. A., P. I. Bird, R. W. Carrell, F. C. Church, P. B. Coughlin, P. G. Gettins, J. A. Irving, D. A. Lomas, C. J. Luke, R. W. Moyer, et al. 2001. The serpins are an expanding superfamily of structurally similar but functionally diverse proteins. Evolution, mechanism of inhibition, novel functions, and a revised nomenclature. J. Biol. Chem. 276: 33293-33296.
35. Gadek, J. E., G. A. Fells, R. L. Zimmerman, S. I. Rennard, and R. G. Crystal. 1981. Antielastases of the human alveolar structures. Implications for the protease-antiprotease theory of emphysema. J. Clin. Invest. 68: 889-898.
36. Janoff, A. 1972. Inhibition of human granulocyte elastase by serum alpha-1-antitrypsin. Am. Rev. Respir. Dis. 105: 121-122.
37. Lewis, E. C. 2012. Expanding the clinical indications for a(1)-antitrypsin therapy. Mol. Med. 18: 957-970.
38. Shpacovitch, V., M. Feld, M. D. Hollenberg, T. A. Luger, and M. Steinhoff. 2008. Role of protease-activated receptors in inflammatory responses, innate and adaptive immunity. J. Leukoc. Biol. 83: 1309-1322.
39. Bergin, D. A., K. Hurley, N. G. McElvaney, and E. P. Reeves. 2012. Alpha-1 antitrypsin: a potent anti-inflammatory and potential novel therapeutic agent. Arch. Immunol. Ther. Exp. (Warsz.) 60: 81-97.
40. Jonigk, D., M. Al-Omari, L. Maegel, M. Müller, N. Izykowski, J. Hong, K. Hong, S. H. Kim, M. Dorsch, R. Mahadeva, et al. 2013. Anti-inflammatory and immunomodulatory properties of a1-antitrypsin without inhibition of elastase. Proc. Natl. Acad. Sci. USA 110: 15007-15012.
41. Janciauskiene, S. M., I. M. Nita, and T. Stevens. 2007. Alpha1-antitrypsin, old dog, new tricks. Alpha1-antitrypsin exerts in vitro anti-inflammatory activity in human monocytes by elevating cAMP. J. Biol. Chem. 282: 8573-8582.
42. Yoshida, K., Y. Suzuki, A. Saito, K. Fukuda, C. Hamanishi, and H. Munakata. 2005. Aggrecanase-1 (ADAMTS-4) interacts with alpha1-antitrypsin. Biochim. Biophys. Acta 1725: 152-159.
43. Joosten, L. A., T. O. Crisan, T. Azam, M. C. Cleophas, M. I. Koenders, F. L. van de Veerdonk, M. G. Netea, S. Kim, and C. A. Dinarello. 2015. Alpha-1-antitrypsin-Fc fusion protein ameliorates gouty arthritis by reducing release and extracellular processing of IL-1b and by the induction of endogenous IL-1Ra. Ann. Rheum. Dis. 75: 1219-1227.
44. Grimstein, C., Y. K. Choi, C. H. Wasserfall, M. Satoh, M. A. Atkinson, M. L. Brantly, M. Campbell-Thompson, and S. Song. 2011. Alpha-1 antitrypsin protein and gene therapies decrease autoimmunity and delay arthritis development in mouse model. J. Transl. Med. 9: 21.
45. Yin, H. L., D. J. Kwiatkowski, J. E. Mole, and F. S. Cole. 1984. Structure and biosynthesis of cytoplasmic and secreted variants of gelsolin. J. Biol. Chem. 259: 5271-5276.
46. Suhler, E., W. Lin, H. L. Yin, and W. M. Lee. 1997. Decreased plasma gelsolin concentrations in acute liver failure, myocardial infarction, septic shock, and myonecrosis. Crit. Care Med. 25: 594-598.
47. Mounzer, K. C., M. Moncure, Y. R. Smith, and M. J. Dinubile. 1999. Relationship of admission plasma gelsolin levels to clinical outcomes in patients after major trauma. Am. J. Respir. Crit. Care Med. 160: 1673-1681.
48. Dahl, B., F. V. Schiødt, P. Ott, R. Gvozdenovic, H. L. Yin, and W. M. Lee. 1999. Plasma gelsolin is reduced in trauma patients. Shock 12: 102-104.
49. Lee, P. S., L. R. Drager, T. P. Stossel, F. D. Moore, and S. O. Rogers. 2006. Relationship of plasma gelsolin levels to outcomes in critically ill surgical patients. Ann. Surg. 243: 399-403.
50. Lee, P. S., A. B. Waxman, K. L. Cotich, S. W. Chung, M. A. Perrella, and T. P. Stossel. 2007. Plasma gelsolin is a marker and therapeutic agent in animal sepsis. Crit. Care Med. 35: 849-855.
51. Rothenbach, P. A., B. Dahl, J. J. Schwartz, G. E. O'Keefe, M. Yamamoto, W. M. Lee, J. W. Horton, H. L. Yin, and R. H. Turnage. 2004. Recombinant plasma gelsolin infusion attenuates burn-induced pulmonary microvascular dysfunction. J. Appl. Physiol. 96: 25-31.
52. Osborn, T. M., M. Verdrengh, T. P. Stossel, A. Tarkowski, and M. Bokarewa. 2008. Decreased levels of the gelsolin plasma isoform in patients with rheumatoid arthritis. Arthritis Res. Ther. 10: R117.
53. Aidinis, V., P. Carninci, M. Armaka, W. Witke, V. Harokopos, N. Pavelka, D. Koczan, C. Argyropoulos, M. M. Thwin, S. Möller, et al. 2005. Cytoskeletal rearrangements in synovial fibroblasts as a novel pathophysiological determinant of modeled rheumatoid arthritis. [Published erratum appears in 2005 PLoS Genet. 1: e73.] PLoS Genet. 1: e48.
54. Nurminsky, D., C. Magee, L. Faverman, and M. Nurminskaya. 2007. Regulation of chondrocyte differentiation by actin-severing protein adseverin. Dev. Biol. 302: 427-437.
55. Mateos, J., L. Lourido, P. Fernández-Puente, V. Calamia, C. Fernández-López, N. Oreiro, C. Ruiz-Romero, and F. J. Blanco. 2012. Differential protein profiling of synovial fluid from rheumatoid arthritis and osteoarthritis patients using LCMALDI TOF/TOF. J. Proteomics 75: 2869-2878.
56. Tolosano, E., and F. Altruda. 2002. Hemopexin: structure, function, and regulation. DNA Cell Biol. 21: 297-306.
57. Liang, X., T. Lin, G. Sun, L. Beasley-Topliffe, J. M. Cavaillon, and H. S. Warren. 2009. Hemopexin down-regulates LPS-induced proinflammatory cytokines from macrophages. J. Leukoc. Biol. 86: 229-235.
58. Rolla, S., G. Ingoglia, V. Bardina, L. Silengo, F. Altruda, F. Novelli, and E. Tolosano. 2013. Acute-phase protein hemopexin is a negative regulator of Th17 response and experimental autoimmune encephalomyelitis development. J. Immunol. 191: 5451-5459.
59. McInnes, I. B., and G. Schett. 2007. Cytokines in the pathogenesis of rheumatoid arthritis. Nat. Rev. Immunol. 7: 429-442.
60. Hameed, F., and J. Ihm. 2012. Injectable medications for osteoarthritis. PM&R 4(Suppl. 5): S75-S81.